Table 1.
Key characteristics of patients who started clinical trial treatment
| IO (n=74) | TT (n=43) | NM (n=30) | CT (n=19) | PK (n=10) | Total (n=176) | |
|---|---|---|---|---|---|---|
| Most common index cancer | Colorectal (20, 27%) | Colorectal (14, 33%) | Cutaneous (10, 33%) | Cutaneous (10, 53%) | Glioblastoma (5, 50%) | Colorectal (39, 22%) |
| Median days, consent to treatment | 19 | 19 | 21 | 22 | 9 | 19 |
| Any Gr ≥ 3 AE | 46 (62%) | 26 (60%) | 18 (60%) | 11 (58%) | 2 (20%) | 103 (59%) |
| ≥ 4 Gr ≥ 3 AEs | 8 (11%) | 6 (14%) | 0 (0%) | 3 (16%) | 0 (0%) | 17 (10%) |
| Disease control rate | 19/59 (32%) | 15/36 (42%) | 16/26 (62%) | 7/18 (39%) | 1/2 (50%) | 58/141 (41%) |
| Median months on trial | 2.65 | 1.55 | 3.11 | 3.37 | 1.55 | 2.77 |
IO: Immunotherapy; TT: Targeted Therapy; NM: Novel Molecule; CT: Cellular Therapy (includes oncolytic viruses); PK: Pharmacokinetic Trial; Gr: Grade. “Cutaneous (includes melanoma and squamous cell skin cancer)”. For disease control rate, denominators include only patients who reached the first response assessment timepoint.